Hormonal
Dual GCGR-GLP-1R co-agonists (e.g., cotadutide) reduce body weight and improve NASH histology, but their efficacy in humans is currently comparable to, not superior to, optimized GLP-1R agonists.
For those with Type 2 Diabetes and NASH (liver disease), dual-acting drugs like cotadutide offer a way to target both weight and liver health. However, current human trials show these drugs are roughly as effective as standard GLP-1 injections (like liraglutide) for weight loss, and less effective than the newer GLP-1/GIP combinations (like tirzepatide). They are a viable option, especially if liver health is a primary concern, but may not offer the maximum weight loss benefit available.
The available human data for glucagon-GLP-1 co-agonists assessed in the context of T2D or obesity suggests that the best of these agents may currently be comparable but not superior to results obtained with GLP-1R agonists.
Why this rating
Based on short-term human trials (up to 54 weeks) showing weight loss, but with less enthusiasm than GLP-1/GIP co-agonists.
Source
Glucagon-like peptide-1 receptor co-agonists for treating metabolic disease
Laurie L. Baggio et al. · Molecular Metabolism · 2020
DOI 10.1016/j.molmet.2020.101090
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →